SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
fei
Lv3
400 积分
2021-03-22 加入
最近求助
最近应助
互助留言
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
8天前
已完结
A narrative review of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer
10天前
已完结
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
10天前
已完结
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
16天前
已完结
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
24天前
已完结
Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management
26天前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review
1个月前
已关闭
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
1个月前
已完结
没有进行任何应助
感谢
9天前
感谢
15天前
感谢
1个月前
不需要了【积分已退回】
1个月前
感谢
1个月前
感谢
1个月前
感谢
3个月前
感谢
5个月前
感谢
5个月前
感谢
6个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论